News
Sondaggio FIT 2019
Healthcare Life Sciences & Review dedicates an article to FIT
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
![](https://www.farmaindustriaticino.ch/files/2017/06/IMG_2967-160x160.jpeg)
37a Assemblea generale ordinaria di FIT
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
![](https://www.farmaindustriaticino.ch/files/2017/05/Giampiero-Roncoroni-Zambon-SA-160x160.png)
Linkedin